Identification of Oncogenic Collaborators Providing Insights into the Tumor Suppressing Function of the Eed Polycomb Group (PcG) Gene.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 213-213
Author(s):  
Martin Sauvageau ◽  
Julie Lessard Post-Doc ◽  
Michelle Miller ◽  
Guy Sauvageau

Abstract Polycomb Group (PcG) proteins are key regulators of normal and leukemic hematopoiesis (Lessard and Sauvageau, Nature 2003; Lessard and al., Genes Dev 1999). The eed gene is part of a PcG complex together with Ezh2 and Suz12. Evidence from our laboratory indicates that eed plays a crucial role in the negative regulation of the proliferative capacity of lymphoid and myeloid progenitors, suggesting that this PcG gene is a tumor suppressor. Interestingly, the human eed locus is in a region of chromosome 11 (11q14.2-22.3) which is associated with recurrent deletions in several reported cases of B-CLL, mantle cell lymphoma (MCL) and T-PLL. We now show that when exposed to ionizing radiation at 5 weeks of age, both eedhypo/hypo and eednull/+ mutant mice developed mono- or oligoclonal B and T cell lymphomas with much shorter latencies than observed in littermate controls (50% lethality at 16 wks; 27 wks and 34 wks post-irradiation for eedhypo/hypo, eednull/+ and controls, respectively). We reasoned that new pathways involved in tumorigenesis could be at play in this eed sensitized background, potentially allowing for the identification of new oncogenic collaborators. Therefore, a proviral insertional mutagenesis screen was conducted. Neonatal MMLV infection of eed mutant mice dramatically accelerated the occurrence of B and T cell lymphomas (50% lethality at 16 wks; 22 wks and 26 wks post-infection for eedhypo/hypo,eedhypo/+ and controls, respectively). To characterize retroviral insertions inverse-PCR (IPCR) was performed using genomic DNA isolated from 32 eedhypo/hypo and 27 wild-type tumors. More than 780 IPCR products were recovered and purified. To date, at least 140 retroviral insertion sites (RIS) have been cloned, sequenced and mapped against the mouse genome. Of these, 7 insertion targeting gene loci known to be cancer-related, like Pim1 (n= 7 tumors), Notch1 (n= 14 tumors) and c-Myc (n= 3 tumors) have been identified. In addition, 8 new common insertion sites (CIS), such as Socs1 (n= 6 tumors), Gadd45g (n= 5 tumors) and Fgfr3 (n= 6 tumors) have also been identified. Rearrangements of the Pim1 locus were found in more than 22% of the eed1989/1989 mutant mice whereas none could be found in wild-type littermates. Moreover, RT-PCR analysis indicates that the Pim1 gene is clearly overexpressed in 6 out of 16 eed1989/1989 tumors analyzed compared to wild-type, further supporting a key role for the Pim1 pathway in eed sensitized tumor cells. Thus, the data presented in this study provide evidence that eed has tumor suppressing function. It also points to a novel mechanism of tumor suppression by a PcG protein. Based on these results, it will be interesting to study the status of eed and of the newly identified CISs in human diseases associated with deletions of 11q14.2-22.3.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2622-2622
Author(s):  
Martin Sauvageau ◽  
Guy Sauvageau

Abstract We previously showed that loss of function of the chromatin regulator polycomb group gene (PcG) eed increases susceptibility to lymphoid tumour development (Sauvageau, M. et al. Blood 104 (11); 213). The human eed locus is in a region of chromosome 11 (11q14.2–22.3) which is associated with recurrent deletions in several reported cases of lymphoproliferative diseases. The persistant expression of the wild-type allele of eed is maintained in lymphomas developing in eed+/− animals. This suggests a haploinsufficient function for this gene in preventing tumorigenesis. We recently exploited an insertional mutagenesis screen to identify new cooperative leukemia-inducing genes in eed mutant mice. 325 retroviral insertion sites (RIS) representing 189 different gene loci have been identified by inverse-PCR from a total of 51 lymphomas (25 eed−/− and 26 wild-type). This screen revealed 18 gene loci known to be cancer related and 21 new common insertion sites (CIS) such as sh2d3c (n=4 tumours), fgfr3 (n=15 tumours) and myo5b (n=7 tumours). More than 97% of these CIS were common to both eed mutant and wild-type animals. We next assessed the expression levels of all the genes found in a 100 Kb region of genomic DNA surrounding the CIS identified in our screen in eed mutant and wild-type tumours as well as in the corresponding non-leukemic tissues. Almost 17% of the 48 genes analyzed, including fgfr2, fgfr3, ttc16 and adam15, are aberrantly expressed in non-transformed eed mutant cells when compared to wild-type controls (levels 5–100+ fold). Importantly, several of these genes are either aberrantly expressed in wild-type and eed mutant tumours or represent true CIS thus indicating their possible contribution to early tumour development in eed mutant mice. Moreover, our results do not incriminate eed as a modifier of gene expression once cells are fully transformed, since the oncogenic complement is similar in eed mutant and wild-type leukemias. Collectively, our results link the haploinsufficient role of eed to the appropriate regulation of genes involved in leukemia development.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 197-197 ◽  
Author(s):  
Yan Shou ◽  
Lilia Stepanova ◽  
Brian P. Sorrentino

Three patients in the French X-SCID gene therapy trial have developed T-cell lymphomas associated with integration of a γ c-expressing oncoretroviral vector into the LMO2 locus. These occurrences have raised important questions regarding the safety of gene therapy for hematopoietic diseases: 1) are there unique risk factors for XSCID gene therapy that increase the risk of insertional mutagenesis; 2) does deregulated expression of the vector-encoded γ c gene contribute to transformation; 3) what other genetic lesions may contribute to transformation; 4) can safer vectors be designed that result in lower levels of cellular gene activation? To address these questions, we generated a mouse model of XSCID gene therapy in which both the Arf tumor suppressor gene and the γ c gene were ablated. Bone marrow cells from these Arf −/−, γ c−/− mice were transduced with a MSCV-γ c-ires-GFP vector or with a control MSCV-GFP vector. These transduced cells were then transplanted into lethally-irradiated, CD45.1+ wild-type mice. After 1 year of follow-up, 13 out of 15 mice in γ c-transplanted group developed lymphomas in which 12 were T-cell lymphomas and 1 was a B-cell lymphoma. All of these lymphomas except one were highly positive for GFP expression and were derived from transplanted donor cells. In contrast, there were only 3 lymphomas in the MSCV-GFP control group, all of which lacked GFP expression and two of which were derived from recipient hematopoietic cells. Southern blot analysis of lymphoma cells in the γ c-group demonstrated that the lymphomas were clonally-derived. Ligation-mediated PCR analysis showed integrations near or within established proto-oncogenes in 8 cases demonstrating that T-cell transformation was associated with potential insertional oncogene activation. To examine whether the X-SCID background was essential to the increased transformation rate, a second transplant experiment was performed in which bone marrow cells from ARF−/−, γ c+/+ mice were transduced with a MFG-γ c vector. Only 4 out of 18 mice developed lymphomas at 54 weeks indicating that the XSCID background was required for accelerated transformation and that there was no direct effect from deregulated γ c expression per se. We hypothesized that γ c gene deletion could lead to an increase in the number of early progenitors with a resultant increase in target cells susceptible to insertional mutagenesis. Flow cytometry analysis indeed revealed that XSCID mice had a 5-fold increase in the number of Lin−, c-kit+, Sca1+ progenitor cells in the bone marrow relative to wild-type mice, suggesting potential expansion of common lymphocyte progenitors was present. Our results show that unique risk factors exist for gene therapy-induced transformation in XSCID suggesting that the risk for gene therapy in other hematopoietic disorders may be significantly less. One unique risk factor is likely to be an expansion of early progenitors resulting from loss of γ c gene function. Loss of tumor suppressor gene function is likely to be a required secondary event; a hypothesis that is consistent with the relatively long latency for tumor development in patients. Lastly, our animal model should now allow us to test vector safety modifications such as the use of self-inactivation vectors and chromatin insulators and could define a new γ c vector suitable for use in XSCID gene therapy.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3248-3248
Author(s):  
Sebastian Newrzela ◽  
Christopher Baum ◽  
Zhixiong Li ◽  
Martin-Leo Hansmann ◽  
Sylvia Hartmann ◽  
...  

Abstract After the report of two cases of leukaemia caused by insertional mutagenesis of a retroviral vector in children with SCID, it became clear that safety issues of therapeutic gene transfer must be addressed more thoroughly. We analysed whether gene transfer into mature T cells and haematopoietic stem cells bear the same risk of generating T cell leukaemia through activation of specific T cell oncogenes, such as LMO2, TCL1 and ΔTrkA. To address this issue, we used the Rag-1 mouse model, which allows long term analysis of transplanted T cells and haematopoietic stem cells. We were able to transduce mature T cells and haematopoietic stem cells of C57BL/6 (Ly5.1) donor mice with oncoretroviral vectors expressing LMO2, TCL1 and ΔTrkA. Transduction efficacies of up to 70% were achieved for mature T cells and approximately 90% for haematopoietic stem cells. After transplantation into Rag-1-deficient recipients, stem cell transplanted animals developed T cell lymphomas/leukemia for all investigated oncogenes after characteristic incubation times, mostly of a CD8+CD4+ double positive phenotype. T cell lymphomas were characterised by gross thymic mass, splenomegaly and heavily enlarged lymph nodes, although none of the control- vector- transduced mice developed lymphoma/leukaemia. LM PCR analysis revealed mono- or oligoclonality of the tumours. T cell transplanted animals showed no signs of leukaemia development so far. However, after several attempts, one immortalized T cell progenitor clone could be generated after transduction with LMO2. Our results so far indicate that mature T cells are less susceptible to transformation by known T cell proto-oncogenes, but the studies are still ongoing.


2003 ◽  
Vol 77 (3) ◽  
pp. 2056-2062 ◽  
Author(s):  
Rachel Kim ◽  
Alla Trubetskoy ◽  
Takeshi Suzuki ◽  
Nancy A. Jenkins ◽  
Neal G. Copeland ◽  
...  

ABSTRACT The identification of tumor-inducing genes is a driving force for elucidating the molecular mechanisms underlying cancer. Many retroviruses induce tumors by insertion of viral DNA adjacent to cellular oncogenes, resulting in altered expression and/or structure of the encoded proteins. The availability of the mouse genome sequence now allows analysis of retroviral common integration sites in murine tumors to be used as a genetic screen for identification of large numbers of candidate cancer genes. By positioning the sequences of inverse PCR-amplified, virus-host junction fragments within the mouse genome, 19 target genes were identified in T-cell lymphomas induced by the retrovirus SL3-3. The candidate cancer genes included transcription factors (Fos, Gfi1, Lef1, Myb, Myc, Runx3, and Sox3), all three D cyclins, Ras signaling pathway components (Rras2/TC21 and Rasgrp1), and Cmkbr7/CCR7. The most frequent target was Rras2. Insertions as far as 57 kb away from the transcribed portion were associated with substantially increased transcription of Rras2, and no coding sequence mutations, including those typically involved in Ras activation, were detected. These studies demonstrate the power of genome-based analysis of retroviral insertion sites for cancer gene discovery, identify several new genes worth examining for a role in human cancer, and implicate the pathways in which those genes act in lymphomagenesis. They also provide strong genetic evidence that overexpression of unmutated Rras2 contributes to tumorigenesis, thus suggesting that it may also do so if it is inappropriately expressed in human tumors.


2000 ◽  
Vol 74 (20) ◽  
pp. 9786-9791 ◽  
Author(s):  
Shin-ichi Yanagawa ◽  
Jong-Seo Lee ◽  
Kazuhiro Kakimi ◽  
Yukihiro Matsuda ◽  
Tasuku Honjo ◽  
...  

ABSTRACT In contrast to wild-type mouse mammary tumor virus (MMTV), the MMTV mutants with specific deletions in the U3 region of their long terminal repeats cause T-cell lymphomas. In 30% of T-cell lymphomas arising in BALB/c mice infected with MLA-MMTV, a leukemogenic MMTV mutant, we have found that MMTV proviruses were integrated into a short region of theNotch1 genome, so that truncated Notch1transcripts encoding the transmembrane and the cytoplasmic domains of Notch1 protein could be expressed. Thus, Notch1 is a major target of provirus insertional mutagenesis in these T-cell lymphomas.


2019 ◽  
Vol 3 (12) ◽  
pp. 1788-1794 ◽  
Author(s):  
Soumya Sundara Rajan ◽  
Lingxiao Li ◽  
Mercedes F. Kweh ◽  
Kranthi Kunkalla ◽  
Amit Dipak Amin ◽  
...  

Key Points CRISPR/Cas9 genomic editing of wild-type hematopoietic stem cells generates Npm1-Alk, leading to ALK+ large-cell lymphomas in recipients. CD30+ postthymic T-cell lymphomas are polyclonal but transplantable to secondary recipients with long latency.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 289-289 ◽  
Author(s):  
Akihiro Konno ◽  
G. Jayashree Jagadeesh ◽  
Daniele Moratto ◽  
Marita Bosticardo ◽  
Ingeborg Holt ◽  
...  

Abstract Gene transfer into peripheral blood lymphocytes has several potential applications including the correction of genetic diseases and therapeutic approaches for HIV-1 infection and cancer. Integrating gene transfer system based on murine oncoretroviruses are a convenient tool for such strategies. However, the recent occurrence of uncontrolled clonal T cell expansions in two patients treated with retroviral gene transfer for X-linked severe combined immune deficiency has raised the concern of the risk of insertional oncogenesis associated with the clinical use of integrating viral systems. In vitro studies have indicated that murine viral vectors tend to integrate in the vicinity of transcription start regions of the genome, thus providing a possible mechanism for oncogene activation, however, data from clinical gene transfer trials is lacking. We are following patients affected with adenosine deaminase (ADA) deficiency who have received T-lymphocyte-directed, retroviral-mediated gene transfer starting in 1990. The first treated patient received the last infusion of gene-corrected cells 12 years ago, has never shown any sign of lymphoproliferation and still carries ~20% of gene-corrected peripheral blood lymphocytes. We set out to study the integration sites in the cells of this patient with the aim of mapping the regions involved by retroviral integrations, determining their localization with respect to known genes, and assessing whether a preferred pattern could be defined. Genomic DNA was prepared from stored lymphocyte samples dating 1991, 1992, 1995, 1998, 2000, and 2003. By inverse PCR and ligation-mediated PCR, we have identified ~860 bona fide insertion sites. Search for homology within the human genome using BLAT returned ~330 unique hits that involved a variety of genes, including transcription factors and oncogenes (e.g. RUNX1, STAT5, FYN). To evaluate the distribution pattern of these integration sites, 2000 randomly generated data sets of genomic coordinates were assembled and their distribution relative to annotations of the human genome was analyzed. A preliminary comparison of the random distribution to our experimental samples showed that retroviral integrations in cells obtained from the patient were significantly skewed toward regions within 2 kb of genes (p<0.002) and CpG islands (p<0.001). These results suggest that, similar to what observed in murine fibroblast and human cancer cell lines, transcriptionally active regions of the genome may be preferred targets of retroviral vectors in human primary T lymphocytes. At the same time, our observations show that the resulting integration events are compatible with long-term, event-free in vivo survival of gene-modified cells in clinical settings.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 197-197
Author(s):  
Akiko Nagamachi ◽  
Hiroya Asou ◽  
Hirotaka Matsui ◽  
Yuko Ozaki ◽  
Daisuke Aki ◽  
...  

Abstract In attempts to isolate myeloid tumor-suppressor genes responsible for 7q deletion, we identified a common microdeletion cluster in chromosome subband 7q21.2 by microarraybased CGH analyses of JMML (ASH Annual Meeting, 2006). This region was also deleted in nearly 30% of unselected adult MDS/AML patients, mostly as a part of monosomy 7 or larger 7q deletions. In this region, there are three poorly-characterized genes (Miki = LOC253012, Kasumi = Samd9, and Titan = Samd9L). Miki encoding a centrosomal protein is likely involved in myelodysplasia and chromosomal instability, which are characteristic of -7/7q- MDS/AML, as is presented in this meeting elsewhere. Kasumi (Samd9) and Titan (Samd9L) are related genes that encode 60% homologous proteins. Neither Kasumi nor Titan has homology with any other proteins or contain known functional motifs. Kasumi and Titan were ubiquitously expressed at a relatively constant level. However, in six cell lines derived from MDS/AML patients harboring monosomy 7, Kasumi protein was barely detectable, whereas Titan expression levels were roughly half of those in other AML cells. The mouse genome contains only Titan and lacks Kasumi gene, suggesting that the function of these two gene products are overlapping. We started to characterize these genes by generating mice deficient in Titan (titan−/−). titan−/− mice appear normal and no hematological abnormalities have been observed, suggesting that additional gene alterations are required for leukemia development. To address this issue, retroviral insertional mutagenesis was applied to the mice. Virus infection induced acute leukemia in homozygous (titan−/−) and heterozygous (titan+/−) mice with higher morbidity and mortality than in wild-type (titan+/+) littermates. Leukemias developed in titan+/+ mice were mainly of T-cell lineage. By contrast, those developed in titan−/− and titan+/− mice were negative for lymphoid markers but expressed various combination of cell surface markers for myeloid (Gr1), monocytic (Mac1), erythyroid (Ter119) and megakaryocytic (CD61) progenitors. Histopathology demonstrated that leukemia cells infiltrated the liver, lung, kidneys and spleen, and a portion of the infiltrated cells were maturated. These data suggests that leukemias that developed in titan-deficient mice represent stem cell malignancy rather than AML. Inverse PCR detected two common integration sites (CIS) specific for titan−/− and titan+/− mice, which induced deregulated expression of a zinc finger transcription factor, Evi1, and a histone demethylase, Fbxl10. In addition, although it was not a CIS, TGFβ was isolated as a major viral integration site in one tumor. These results demonstrated that haploinsufficiency and deficiency of Titan predispose leukemia development through inhibition of TGFβ-mediated signaling or an epigenetic change. Recently, deleterious mutations in the Titan gene were reported to be involved in Normophosphatemic Familial Tumoral Carcinosis, a rare autosomal recessive disease in five families of Jewish-Yemenite origin. Impairment of cell migration is suspected to be a cause of this disease and, indeed, wound healing test revealed that fibroblasts established from titan−/− and titan+/− mice migrate slower than those established from wild-type mice. Relevance of the impairment of cell migration to development of leukemia in titan-deficient mice is currently under investigation.


1998 ◽  
Vol 187 (2) ◽  
pp. 185-196 ◽  
Author(s):  
Jorge H. Caamaño ◽  
Cheryl A. Rizzo ◽  
Stephen K. Durham ◽  
Debra S. Barton ◽  
Carmen Raventós-Suárez ◽  
...  

The nfkb2 gene is a member of the Rel/NF-κB family of transcription factors. COOH-terminal deletions and rearrangements of this gene have been associated with the development of human cutaneous T cell lymphomas, chronic lymphocytic leukemias, and multiple myelomas. To further investigate the function of NF-κB2, we have generated mutant mice carrying a germline mutation of the nfkb2 gene by homologous recombination. NF-κB2–deficient mice showed a marked reduction in the B cell compartment in spleen, bone marrow, and lymph nodes. Moreover, spleen and lymph nodes of mutant mice presented an altered architecture, characterized by diffuse, irregular B cell areas and the absence of discrete perifollicular marginal and mantle zones; the formation of secondary germinal centers in spleen was also impaired. Proliferation of NF-κB2–deficient B cells was moderately reduced in response to lipopolysaccharide, anti-IgD-dextran, and CD40, but maturation and immunoglobulin switching were normal. However, nfkb2 (−/−) animals presented a deficient immunological response to T cell–dependent and –independent antigens. These findings indicate an important role of NF-κB2 in the maintenance of the peripheral B cell population, humoral responses, and normal spleen architecture.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2234-2234
Author(s):  
Maria Luisa Sulis ◽  
Teresa Palomero ◽  
Pedro J. Real ◽  
Kelly C. Barnes ◽  
Peter Aplan ◽  
...  

Abstract Transgenic mouse models of T-cell oncogenes such as TAL1 and LMO1, have confirmed their critical role in the development of T-lymphoblastic lymphoma (T-LL). In addition, retroviral insertional mutagenesis (RIM) in mice is a powerful system for the identification of genes involved in T-cells leukemogenesis. However, incomplete knowledge of the pathogenesis of T-ALL limits the ability to stratify patients and to deliver tailored therapy accordingly. Thus, a major goal is to identify common oncogenic pathways downstream of T-cell oncogenes that can serve as therapeutic targets for the treatment of T-ALL. We hypothesize that T-cell oncogenes operate through a limited number of oncogenic pathways with distinct gene expression profiles. Furthermore, we propose that gene expression profiling of murine models of T-cell lymphomas, which harbor specific genetic lesions, will serve to identify such oncogenic pathways and to establish a molecular classification of T-ALL. To test this hypothesis we have analyzed normal thymus and mouse T-cell lymphomas originated from retroviral insertional mutagenesis (n=11) and transgenic and knock-outs models (n=30) using Affymetrix 430A2.0 microarrays. Unsupervised analysis clearly distinguishes tumor samples from normal thymus and clusters the tumors into three major groups. TAL1, LMO2 and E2 proteins are known to be part of a transcriptional complex and to cooperate in T-cell leukemogenesis by suppressing E2A function. Accordingly, mouse tumors originating in TAL1, TAL1/LMO2 transgenic and E2A knock-out mice share a common gene expression signature and cluster together. Supervised analysis of tumors generated by retroviral mutagenesis showed increased expression of the proviral tagged genes and identified corresponding known downstream targets. Nearest neighbor analysis identified high levels of Notch1 expression in tumors with proviral insertion in the Notch1 locus and in tumors generated in the TAL1/, TAL1/LMO2, OLIG2/LMO1, ThPOK and Ikaros mouse models, which harbored activating mutations in NOTCH1. Our results demonstrate that gene expression profiling identifies common oncogenic pathways in T-cell tumors generated in mice, establishes common mechanisms of transformation for several T-ALL oncogenes and allows coupling of poorly characterized genes identified in proviral insertional sites with well characterized oncogenes and downstream molecular pathways. The identification of mechanisms of T-cell transformation common to tumors of different origin lays the ground for the identification of new therapeutic targets for the treatment of T-ALL.


Sign in / Sign up

Export Citation Format

Share Document